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Short title: Electrical Stimulation of LES for post-LSG GERD 
 
Background: 
Laparoscopic Sleeve Gastrectomy (LSG) can result in de novo and worsen preexisting 
Gastroesophageal Reflux Disease (GERD). Post-LSG patients with GERD refractory to 
Proton Pump Inhibitors (PPI) usually undergo more invasive, anatomy-altering gastric 
bypass surgery (RYGB). Lower Esophageal Sphincter (LES) electrical stimulation (ES) 
preserves the anatomy and has been shown to improve outcomes in GERD patients. 
 
Objective: 
To evaluate the safety and efficacy of LES-ES in post-LSG patients with GERD not 
controlled with maximal PPI therapy. 
 
Setting: 






Patients with LSG-associated GERD partially responsive to PPI underwent LES-ES. GERD 
outcomes pre- and post-stimulation were evaluated based on Quality of Life (GERD-
HRQL), esophageal acid exposure (after 6-12 months) and PPI use. 
 
Results: 
17 patients (11 female, 65%), treated at 6 centers between 05/14 - 10/16 with a 
median follow-up of 12 months (min 6-max 24), received LES-ES. Median age was 48.6y 
(IQR 40.5–56), median Body Mass Index 31.7 kg/m2 (27.9–39.3). 
All patients were on at least daily PPI preoperatively; at last follow-up, 7 (41%) were 
completely off-PPI, 5 (29%) took PPI on an intermittent basis and 5 (29%) were on 
single-dose PPI. Median GERD-HRQL scores improved from 34 (on-PPI, 25-41) at 
baseline to 9 (6-13) at last follow-up (off-PPI, p<0.001). Percentage of time with 
esophageal pH<4 improved from 13.2%(3.7–30.7) to 5.8%(1.1–54.4), p=0.01. 
 
Conclusion: 
LES-ES in post-LSG patients suffering from symptomatic, PPI-refractory GERD resulted 
in significant improvement of GERD-symptoms, esophageal acid exposure and need for 
PPI. Preserving the post-LSG anatomy, it offers a valid option for patients unable or 
unwilling to undergo RYGB. 
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Introduction: 
 
Morbid obesity is recognized as a major public health issue that contributes to serious 
health risks. Bariatric surgery has been demonstrated to be the most efficacious method 
to achieve sustainable weight loss and resolution of comorbidities among the morbidly 
obese(1, 2). 
In recent years, laparoscopic sleeve gastrectomy (LSG) has become the most frequently 
preformed bariatric procedure, in both, a stand-alone or a prelude to staged duodenal 
switch (1, 3). Contributing factors to its widespread acceptance are technical simplicity, 
low morbidity and results comparable to Roux-Y Gastric Bypass (RYGB), for weight loss 
and control of metabolic syndrome(2). Preservation of anatomy predisposes this 
procedure for patients in need for access to the biliary tree, stomach and duodenum. 
Further, complications associated with RYGB such as dumping syndrome, small bowel 
obstruction due to internal hernia and nutrient deficiencies are avoided. 
 
The prevalence of Gastroesophageal Reflux Disease (GERD) in bariatric patients is 
increased; up to 70% of patients have symptomatic GERD and half of patients 
undergoing bariatric surgery have erosive esophagitis in the preoperative evaluation(4, 
5). In contrast to RYGB, there are reports of SG worsening pre-existing GERD or causing 
new-onset GERD(6-9). So far, GERD after LSG, not sufficiently controlled by medication, 
is addressed by conversion to RYGB(10). Yet, as every revisional procedure, this carries 
an increased morbidity but particularly abrogates the initial intention of LSG as 
anatomy-preserving procedure(10, 11). 
 
Electrical stimulation of the Lower Esophageal Sphincter (LES) is a novel surgical option 
that has been shown to normalize LES pressure and esophageal acid exposure in GERD 
patients without altering the anatomy(12-15). The aim of this study was to evaluate the 
safety and efficacy of electrical LES stimulation in LSG patients with refractory GERD 




Anonymized data of post-LSG patients with a follow-up of >6 months and GERD treated 
with LES stimulation therapy (EndoStim®, BV, Nijmegen, Netherlands; currently filing 
for FDA approval) were extracted from a prospective, web-based, international multi-
center registry, tracking symptomatic and objective outcome, registered at the clinical 
trials registry of the National Institutes of Health (NCT 02441400). Patient symptoms, 
medication use and esophageal tests pre- and post-LES stimulation therapy were 
analyzed. 
 
Surgical technique and LES stimulation: 
Two electrodes were sewn into the esophageal wall laparoscopically 1cm apart in the 
LES region (Fig 1), the lead body was exteriorized through one of the laparoscopic ports 
and the pulse generator was implanted in a subcutaneous pocket in the left upper 
abdomen. Small hiatal hernias (<2cm) were addressed with hiatoplasty (posterior or 
com in d ant  i   and p st  i  ) hiat p ast  at th  su g  ns’ disc  ti n. P   p  ativ  
bigger hiatal hernias were a contraindication. LES stimulation was initiated during the 
implant procedure, PPI therapy was discontinued 3-4 weeks later. Patients with 
residual or recurrent symptoms despite optimization of their stimulation parameters 
were treated with rescue GERD medications. 
Th  standa diz d stimu ati n pu s  (215μs wid  and n mina    5mA in amp itud ) is 
monophasic followed by a charge-balancing phase. The stimulation pulse is delivered at 
a rate of 20Hz and continues for a period of 30 minutes. Up to twelve 30-minute 
sessions are delivered per day. Electrical stimulation can wirelessly be optimized to 
tailor the delivery to individual needs by adjusting amplitude and electrode polarity to 
address suboptimal symptom or pH response beginning 6 months after the procedure. 
 
Symptom assessment and pH-monitoring: 
GERD symptoms were assessed using the validated GERD–HRQL- questionnaire which 
provides a composite score of maximum 50 points(16). Assessment was carried out at 
baseline (prior to implantation) with the patient on PPI therapy and at every follow-up 
(every 6 months in the first 2 years, then yearly). Esophageal acid exposure was 
assessed at baseline and after 6-12 months of LES stimulation therapy using 24-hour 
esophageal pH-metry. Sensors were positioned in the esophageal body 5cm above the 
manometric upper border of the LES with the patient off PPI therapy for at least 5 days. 
Further, use of PPI medication and anthropometric parameters were recorded at each 
follow-up visit. 
 
Descriptive statistics were used for demographic variables. Data were compared using 
two-tai  d Stud nt’s t-test, Friedman test or Wilcoxon signed-rank test. A two- sided p-
value of <0.05 was considered significant. Data were reported as medians with 




17 patients (11 female, 65%), treated at 6 centers between 05/14 - 10/16 with a 
median follow-up of 12 months (min 6- max 24), were included. No patient was lost to 
follow-up. Median age was 48.6y (IQR 40.5 – 56), median BMI at time of implantation 
was 31.7 kg/m2 (27.9 – 39.3), there was no significant decrease during the follow-up 
(after 6 months 28.5kg/m2 (23.9 – 34.8), after 12 months 29.8kg/m2 (23.6 – 35), 
p=0.2).  
 
There were no serious adverse events related to the device or procedure, and there 
were no reoperations or device removals within the follow-up. 
 
Preoperatively, all patients were using daily double- or higher dose PPI (single dose 
defined as 40mg pantoprazole or equivalent). At their last follow-up, 5 patients (29%) 
were on single dose-, 7 (41%) completely off-PPI and 5 (29%) took PPI on an 
intermittent basis. 
 
All patients reported improvement in their GERD symptoms after initiation of LES 
stimulation. Median GERD-HRQL scores (Fig 2a and 2b) at baseline (on-PPI) were 34 
(25-41) which improved to 9 (6-13) at last follow-up (off-PPI, p<0.001). 
 
Evolution of median esophageal acid exposure is depicted in Figure 3. Percentage of 
time with pH<4 improved from 13.2% (3.7 – 30.7) to 5.8% (1.1 – 54.4), p=0.01; 
normalization (< 4% of esophageal pH < 4) was observed in 7 (41%) and worsening in 
2 patients (12%). Yet, in both patients, GERD-HRQL improved and both were 




This study reports the outcome of post-LSG patients with refractory GERD addressed 
with electrical stimulation of the LES over a median follow-up of a year (range 6-14 
months). This treatment led to a significant improvement of both GERD symptoms, 
esophageal acid exposure and reduction in GERD medication use. 
 
Morbid obesity is associated with GERD and esophageal motility disorders, the 
prevalence is estimated up to 70%(4, 5, 17-19). There is a linear relationship not only 
between BMI and GERD, but rather between central obesity and GERD(20). Yet, central 
obesity complicates bariatric procedures and is one of the main reasons - together with 
the resulting comorbidities – for the popularity of LSG(21). Morbid obesity increases 
the intraabdominal pressure having an effect on intragastric pressure and the 
gastroesophageal pressure gradient, and leads further to a higher rate of hiatal hernias 
and postprandial transient LES relaxations (TLESR)(22). Further, LES pressures are 
lowered, and there is high incidence of ineffective esophageal motility(23, 24). 
 
The effects of LSG on GERD are controversially discussed, yet the vast majority of 
studies report a worsening of pre-existing and a substantial rate of de-novo GERD(8, 25-
27).  
 
Depending on duration of follow-up, measures to detect GERD and operative technique, 
the incidence of de novo post-LSG GERD ranges up to 47% in symptoms and 63.5% 
endoscopically(7, 8, 19, 26). Further troubling is a high rate of asymptomatic GERD in 
bariatric patients of so far unknown importance and an association of worse outcome 
after LSG with GERD regarding weight loss and resolution of comorbidities(8, 28, 29). 
Post-LSG Barrett’s  s phagus has a high incid nc  and  ccu s un   at d t  
symptoms(30). In addition, with rising numbers of LSG, this problem might aggravate in 
the near future as most studies so far describe a selected patient group with less GERD; 
so far, most patients with pre-existing higher-grade GERD are denied the benefits of LSG 
and proposed RYGB instead(31). 
 
A multitude of factors have an influence on post-LSG GERD after LSG(27). Technical 
factors such as proximity of the staple to the LES have an impact on its function, 
disruption of sling fibers lead to a decrease of LES pressure and shortening of LES, as 
showed by manometric pre- and postoperative evaluation(5, 24). LSG results in 
decreased gastric compliance provoking a possible increase of TLESR(22). Further, 
another study showed a high rate of ineffective esophageal peristalsis after LSG(23). 
 
Electrical Stimulation of the LES leads to a sustained reduction of GERD symptoms and 
improvement of esophageal acid exposure in the majority of patients(12-14). It is a 
procedure with minimal morbidity, also in the small group reported here. The 
underlying mechanisms have yet to be elucidated in detail; it has a positive impact on 
LES pressure and LES length and may improve esophageal motility and reduce the 
frequency of TLESR(15). In the context of post-LSG GERD, it offers the distinctive 
advantage of preserving the anatomy. This study shows it to be safe and technically 
feasible. It offers a significant improvement of esophageal acid exposure with a 
normalization in almost half of patients. A longer follow-up might lead to an even higher 
rate, as the maximum effect has to be expected after 9 months, yet the median objective 
follow-up in this study was 6 months. Symptomatic control, in terms of PPI use and 
standardized questionnaires, was excellent, and comparable to RYGB. Even more, the 
patient population included was non-responsive to PPI and had a rather high 
esophageal acid exposure. 
 
There are limitations to this study. It is an open-label, multicenter design with a small 
sample size including a heterogeneous patient population from a self-reported patient 
registry. Postbariatric patients are different than other GERD patients with different 
comorbidity profiles and probable different reasons for GERD. These data are 
preliminary; a larger sample size with a longer follow-up in a prospective, randomized, 
double-blind, sham-controlled design is needed to validate these results. 
 
Conclusions: 
Electrical stimulation of LES in post-LSG patients suffering from symptomatic GERD 
refractory to medication led to a significant improvement of GERD-symptoms, 
esophageal acid exposure and overall decrease of need for PPI. Preserving the post-LSG 
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Tables and Figures: 
Figure 1: Electrodes sewn into the esophageal wall beneath the Lower Esophageal 
Sphincter 
Figure 2a: Evolution of symptoms, assessed with the GERD-HRQL score (max 50), 
shows a significant and sustained improvement over time. Depicted in both figures are 
medians (box) with interquartile ranges (error bars). 
Figure 2b: Improvement of symptoms from preoperative baseline (left column) to last 
follow-up (right column), according to postoperative proton pump inhibitor use.  
Figure 3: Evolution of esophageal acid exposure, in percentage of time with esophageal 
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